BRIEF-Azurrx Biopharma Identifies Asymchem As Potential Partner Of Choice For MS1819 Phase 3 Clinical Trial Drug Production

Reuters
10 Nov 2020

Nov 10 (Reuters) - AzurRx BioPharma Inc :

* AZURRX BIOPHARMA IDENTIFIES ASYMCHEM AS POTENTIAL PARTNER OF CHOICE FOR MS1819 PHASE 3 CLINICAL TRIAL DRUG PRODUCTION

* AZURRX BIOPHARMA - ASYMCHEM TO IMPLEMENT FERMENTATION, VERIFY PROTEIN EXPRESSION AND ULTIMATELY FINE-TUNE TECHNOLOGY SUITABLE FOR PRODUCTION OF MS1819

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10